Zhi-Qi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhi-Qi Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Ran Liu
Department of Pharmacy, Binzhou Medical University, Yantai, Shandong Province, China
2 shared publications - Zhenhong Xia
Department of Pharmacy, Binzhou Medical University, Yantai, China
2 shared publications - Feixue Ni
School of Pharmacy Binzhou Medical University Yantai China
1 shared publication Geng Tian
Department of Pharmacy, Binzhou Medical University School of Enology, Yantai, Shandong, China
1 shared publication- Wen-Guo Jiang
Department of Pharmacy, Binzhou Medical University, Yantai, Shandong Province, China
1 shared publication - Wen-Zhuo Ming
Department of Pharmacy, Binzhou Medical University, Yantai, Shandong Province, China
1 shared publication
Latest Publications
- Open Access
- 8 July 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (7)
Hengtang Capsule Improves Glucose and Lipid Metabolism and Oxidative Stress Levels in Db/db Mice and Underlying Mechanisms
Objectives: Diabetes involves abnormalities in glucolipid metabolism, with oxidative stress serving as a major contributing factor. The Hengtang capsule is a dietary supplement that helps maintain healthy blood glucose (BG) and lipid levels as well as healthy body weight. Given the antioxidative stress effects of various components in the Hengtang capsule, the Hengtang capsule may offer a novel therapeutic approach for treating type 2 diabetes mellitus (T2DM). In this study, we investigated the ability of the Hengtang capsule to treat T2DM through a combination of network pharmacology and animal experiments. Methods: The underlying mechanisms of the Hengtang capsule in treating T2DM were predicted via network pharmacology. After conducting an experiment for 4 weeks, the oral glucose tolerance test (OGTT), fasting blood glucose (FBG), liver function, lipid profile, and oxidative stress markers of the db/db mice were measured. Additionally, the effectiveness of the Hengtang capsule as an antidiabetic agent was assessed via hematoxylin and eosin (HE) staining and immunofluorescence assays. Results: Five core targets, including TP53, AKT1, CTNNB1, STAT3, and EGFR, were identified. The targets were associated mainly with the PI3K/Akt, lipid and atherosclerosis, RAGE/AGE, and FoxO signaling pathways. Additionally, treatment with the Hengtang capsule resulted in significant reductions in the area under the curve (AUC), FBG, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), aspartate transaminase (AST), alanine transaminase (ALT), and malondialdehyde (MDA) compared to those of the negative control group. In contrast, the concentrations of high-density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), and the area occupied by insulin-positive cells increased significantly. Moreover, improvements in liver histopathology were observed. Conclusion: The results showed that the Hengtang capsule may exert therapeutic effects on diabetes by modulating glycolipid metabolism and oxidative stress.
- 8 July 2025
- Published by SAGE Publications in Natural Product Communications
- Vol. 20 (7)
Open AccessHengtang Capsule Improves Glucose and Lipid Metabolism and Oxidative Stress Levels in Db/db Mice and Underlying Mechanisms
Objectives: Diabetes involves abnormalities in glucolipid metabolism, with oxidative stress serving as a major contributing factor. The Hengtang capsule is a dietary supplement that helps maintain healthy blood glucose (BG) and lipid levels as well as healthy body weight. Given the antioxidative stress effects of various components in the Hengtang capsule, the Hengtang capsule may offer a novel therapeutic approach for treating type 2 diabetes mellitus (T2DM). In this study, we investigated the ability of the Hengtang capsule to treat T2DM through a combination of network pharmacology and animal experiments. Methods: The underlying mechanisms of the Hengtang capsule in treating T2DM were predicted via network pharmacology. After conducting an experiment for 4 weeks, the oral glucose tolerance test (OGTT), fasting blood glucose (FBG), liver function, lipid profile, and oxidative stress markers of the db/db mice were measured. Additionally, the effectiveness of the Hengtang capsule as an antidiabetic agent was assessed via hematoxylin and eosin (HE) staining and immunofluorescence assays. Results: Five core targets, including TP53, AKT1, CTNNB1, STAT3, and EGFR, were identified. The targets were associated mainly with the PI3K/Akt, lipid and atherosclerosis, RAGE/AGE, and FoxO signaling pathways. Additionally, treatment with the Hengtang capsule resulted in significant reductions in the area under the curve (AUC), FBG, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), aspartate transaminase (AST), alanine transaminase (ALT), and malondialdehyde (MDA) compared to those of the negative control group. In contrast, the concentrations of high-density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), and the area occupied by insulin-positive cells increased significantly. Moreover, improvements in liver histopathology were observed. Conclusion: The results showed that the Hengtang capsule may exert therapeutic effects on diabetes by modulating glycolipid metabolism and oxidative stress.
- Open Access
- 5 October 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (10)
Isobavachalcone Inhibits Hyperglycemia and Hyperlipemia in Type 2 Diabetes and the Underlying Mechanisms
Objective: The aim of this research was to probe the effect of isobavachalcone inhibiting the high-fat diet (HFD) and streptozotocin (STZ) induced hyperglycemia and hyperlipemia in mice and its underlying mechanisms. Methods: A mouse model with type 2 diabetes mellitus (T2DM) was established by the HFD and low-dose streptozotocin. T2DM mice were treated with 10 mg/kg of isobavachalcone for 4 weeks. The levels of fasting blood glucose (FBG), blood lipids, and relative proteins in the PI3K/AKT signaling pathway as well as the histological structural changes in the liver were determined. Results: The results showed that the expression levels of FBG (42%, P < .001), triglyceride (70%, P < .001), and glucose transporter 2 were significantly reduced by isobavachalcone. The proteinic and mRNA expressions of IRS1, PI3K, and AKT genes of T2DM mice were dramatically increased with the isobavachalcone treatment. Furthermore, isobavachalcone ameliorated the morphology of the liver in T2DM model mice. Conclusion: The results suggested that isobavachalcone controls the development of T2DM as well as the regulatory mechanism involved in glucose and lipid metabolism through the PI3K/AKT signal pathway in the liver.
- 5 October 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (10)
Open AccessIsobavachalcone Inhibits Hyperglycemia and Hyperlipemia in Type 2 Diabetes and the Underlying Mechanisms
Objective: The aim of this research was to probe the effect of isobavachalcone inhibiting the high-fat diet (HFD) and streptozotocin (STZ) induced hyperglycemia and hyperlipemia in mice and its underlying mechanisms. Methods: A mouse model with type 2 diabetes mellitus (T2DM) was established by the HFD and low-dose streptozotocin. T2DM mice were treated with 10 mg/kg of isobavachalcone for 4 weeks. The levels of fasting blood glucose (FBG), blood lipids, and relative proteins in the PI3K/AKT signaling pathway as well as the histological structural changes in the liver were determined. Results: The results showed that the expression levels of FBG (42%, P < .001), triglyceride (70%, P < .001), and glucose transporter 2 were significantly reduced by isobavachalcone. The proteinic and mRNA expressions of IRS1, PI3K, and AKT genes of T2DM mice were dramatically increased with the isobavachalcone treatment. Furthermore, isobavachalcone ameliorated the morphology of the liver in T2DM model mice. Conclusion: The results suggested that isobavachalcone controls the development of T2DM as well as the regulatory mechanism involved in glucose and lipid metabolism through the PI3K/AKT signal pathway in the liver.